cryptocurrency values, Featured snippets

On December 13th, Shaanxi Supervision Bureau of the State Financial Supervision and Administration issued an administrative penalty message showing that Baoji Central Branch of Ancheng Property Insurance Co., Ltd. was fined 60,000 yuan for giving benefits other than the insurance contract. The salesman of Baoji Central Branch of Ancheng Property Insurance Co., Ltd. was warned and fined 10,000 yuan.Minister of Agriculture of Ukraine: Ukraine is willing and ready to supply food to Syria.The Chairman of the Sudan Sovereignty Committee and the Turkish President made a phone call focusing on the situation in Sudan. On December 13th, local time, Borhan, Chairman of the Sudan Sovereignty Committee and Commander-in-Chief of the Armed Forces, made a phone call with Turkish President Erdogan, focusing on the situation in Sudan. Erdogan said during the call that Turkey is willing to mediate between Sudan and the United Arab Emirates to resolve the contradictions between the two countries. Since the outbreak of armed conflict in Sudan last year, Sudanese government officials have repeatedly accused the UAE government of supporting the Sudan Rapid Support Force, which has caused tension between the two countries. At the end of last year, the two countries expelled each other's diplomats. Erdogan also said that Turkey opposes foreign interference in Sudan's internal affairs and supports Sudan in safeguarding national unity and territorial integrity and restoring peace and stability. (CCTV News)

The Bank of Italy said that the economy may only grow by 0.5% this year, and the Bank of Italy said in a statement on Friday that the gross domestic product (GDP) will increase by 0.5% in 2024. If seasonal and calendar effects are not taken into account, this figure will increase to 0.7%, but it is lower than the government's estimate of 1% in the budget. In addition, GDP growth is expected to be 0.8% in 2025 and 1.1% in 2026. It is estimated that the unified average inflation rate in the EU will be 1.1% in 2024, which is the same as the estimated value in October, 1.5% in 2025 and 1.6% in 2025.There is an urgent need for compound talents in the sustainable financial industry, so Gao Jin launched the sustainable financial curriculum system. On December 12th, at the "2024 China Sustainable Investment Development Forum", Shanghai Institute of Advanced Finance of Shanghai Jiaotong University first launched the sustainable financial curriculum system, becoming the first domestic university to build a special talent training system for the sustainable financial industry. Wang Tan, Vice President Gao Jin, Professor of Finance and Director of the Academic Committee of the Research Center for Sustainable Investment, said that the existing curriculum system of universities at home and abroad has many problems, such as low number, low matching degree and insufficient core courses. The sustainable financial industry is in urgent need of compound talents with relevant background of sustainable development and financial knowledge. According to Wang Tan, the current curriculum system of high-quality sustainable finance is still a basic version, and it will be continuously adjusted, optimized and improved according to industry trends and market demand in the future, so as to cultivate talents who are in short supply and meet market demand better. The Research Report on China Carbon Market System was released on the same day. The report makes an in-depth study on the future development of China's carbon market system and puts forward forward forward forward-looking suggestions. For example, the current national carbon market is still in the early stage of development, and it is suggested that the future national carbon market should focus on system design, basic capacity building, and the degree of marketization in line with the international carbon market. (The Paper)Nearly 30 listed companies announced after-hours that their products would be selected, and the tenth batch of centralized drug procurement (centralized drug procurement) organized by the state was opened in Shanghai yesterday. According to incomplete statistics, as of press time, it includes Fuyuan Pharmaceutical, Yifan Pharmaceutical, ST Tiansheng, Hokuriku Pharmaceutical, Haizheng Pharmaceutical, Zhongheng Group, Yuandong Bio, Kelun Pharmaceutical, China Resources Shuanghe, Sinopharm Modern, Lingkang Pharmaceutical, Xuantai Pharmaceutical, Jiuzhou Pharmaceutical, Kang Enbei, Laimei Pharmaceutical, Kanghong Pharmaceutical, Huasen Pharmaceutical, Borui Pharmaceutical, Xianzeng Pharmaceutical. Among them, Kelun Pharmaceutical announced that 12 kinds of drugs, such as sodium acetate Ringer injection, sodium bicarbonate Ringer injection and gliclazide tablets, were to be selected.

On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.Market News: The United Arab Emirates will restrict oil transportation in the case of OPEC+promoting compliance with quotas.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.